

University of Groningen

## A proposal to create an extension to the European baseline series

Wilkinson, Mark; Gallo, Rosella; Goossens, An; Johansen, Jeanne D.; Rustemeyer, Thomas; Sanchez-Perez, Javier; Schuttelaar, Marie L.; Uter, Wolfgang

*Published in:*  
CONTACT DERMATITIS

*DOI:*  
[10.1111/cod.12918](https://doi.org/10.1111/cod.12918)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Wilkinson, M., Gallo, R., Goossens, A., Johansen, J. D., Rustemeyer, T., Sanchez-Perez, J., Schuttelaar, M. L., & Uter, W. (2018). A proposal to create an extension to the European baseline series. *CONTACT DERMATITIS*, 78(2), 101-108. <https://doi.org/10.1111/cod.12918>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# A proposal to create an extension to the European baseline series

Mark Wilkinson<sup>1</sup>, Rosella Gallo<sup>2</sup>, An Goossens<sup>3</sup>, Jeanne D. Johansen<sup>4</sup>, Thomas Rustemeyer<sup>5</sup>, Javier Sánchez-Pérez<sup>6</sup>, Marie L. Schuttelaar<sup>7</sup> and Wolfgang Uter<sup>8</sup>

<sup>1</sup>Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, LS7 4SA, UK, <sup>2</sup>Clinica Dermatologica, Department of Health Sciences (DISSAL), Università di Genova, Ospedale Policlinico San Martino, 16132, Genoa, Italy, <sup>3</sup>Contact Allergy Unit, Department of Dermatology, University Hospital KU Leuven, 3000, Leuven, Belgium, <sup>4</sup>Department of Dermato-Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark, <sup>5</sup>Department of Dermatology, Free University of Amsterdam, 1081 HV, Amsterdam, The Netherlands, <sup>6</sup>Department of Dermatology, Hospital de La Princesa, 28006, Madrid, Spain, <sup>7</sup>Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands and <sup>8</sup>Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nürnberg, 91054, Erlangen, Germany

doi:10.1111/cod.12918

## Summary

**Background.** The current European baseline series consists of 30 allergens, and was last updated in 2015.

**Objectives.** To use data from the European Surveillance System on Contact Allergies (ESSCA) to propose an extension to the European baseline series in response to changes in environmental exposures.

**Methods.** Data from departmental and national extensions to the baseline series, together with some temporary additions from departments contributing to the ESSCA, were collated during 2013–2014.

**Results.** In total, 31 689 patients were patch tested in 46 European departments. Many departments and national groups already consider the current European baseline series to be a suboptimal screen, and use their own extensions to it. The haptens tested are heterogeneous, although there are some consistent themes. Potential haptens to include in an extension to the European baseline series comprise sodium metabisulfite, formaldehyde-releasing preservatives, additional markers of fragrance allergy, propolis, Compositae mix, and 2-hydroxyethyl methacrylate.

**Conclusion.** In combination with other published work from the ESSCA, changes to the current European baseline series are proposed for discussion. As well as addition of the allergens listed above, it is suggested that primin and clioquinol should be deleted from the series, owing to reduced environmental exposure.

**Key words:** Compositae mix; European baseline series; formaldehyde releaser; fragrance; 2-hydroxyethyl methacrylate; propolis; sodium metabisulfite.

*Correspondence:* Dr Mark Wilkinson, Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Harehills Lane, Leeds LS7 4SA, UK. Email: mark.wilkinson15@nhs.net

The present study was not sponsored; the ESSCA had received initial start-up funding from the EU (QLK4-CT-2001-00343 and QLK4-CT-2001-2812) in 2002 to 2004.

The following members of the ESSCA network contributed data to this analysis (ordered by country): Werner Aberer (Graz, Austria), Barbara Ballmer-Weber (Zürich/Luzern, Switzerland), Dagmar Simon (Bern, Switzerland), Jürgen Grabbe (Aarau, Switzerland), Andreas Bircher (Basel), Andrea Bauer (Dresden, Germany), Ulrike Beiteke (Dortmund, Germany), Jochen Brasch (Kiel, Germany), Thomas Fuchs (Göttingen, Germany), Sibylle Schliemann (Jena, Germany), Swen Malte John (Osnabrück, Germany), Vera Mahler (Erlangen, Germany), Elke Weisshaar (Heidelberg, Germany), Ana Giménez Arnau (Barcelona/IMAS, Spain), Juan García Gavín (Vigo, Spain), Pedro Mercader (Murcia, Spain), Inmaculada Ruiz (León, Spain), Juan. F. Silvestre (Alicante, Spain), Maria Pesonen (Helsinki, Finland), Anna Balato (Napoli, Italy), Anna Belloni Fortina (Padova Paediatrica, Italy), Andrea Peserico (Padova, Italy), Rosella Gallo (Genova, Italy), Francesca Larese Filon (Trieste, Italy), Skaidra Valiukeviciene (Kaunas, Lithuania), Thomas Rustemeyer (Amsterdam VU, The Netherlands), Marie-Louise Schuttelaar (Groningen, The Netherlands), Marta Kieć-Świerczyńska (Łódź, Poland), Beata Kręcis (Łódź, Poland), Radosław Spiewak (Krakow, Poland), Mahbub M. U. Chowdhury (Cardiff, UK), Susan M. Cooper (Oxford, UK), Philippa Cousen and Helen L. Horne (Middlesbrough, UK), Natalie Stone (Newport, UK), Ian R. White (London, UK) and Mark Wilkinson (Leeds, UK).

Conflicts of interest. M. Wilkinson: attended a drug advisory board meeting for GlaxoSmithKline (alitretinoin). W. Uter: accepted travel reimbursement and honoraria for presentations given to cosmetic industry (associations) from them, and received a lecture fee from Almirall Hermal for educational lectures on contact allergy. The other authors do not declare a conflict of interest pertinent to this study.

Accepted for publication 29 September 2017

The allergens used in any baseline series constitute an empirical choice reflecting a variety of factors, not least the exposures of the local population. Considerations in choosing substances to test have been reviewed (1), and have guided subsequent revisions of the European baseline series (EBS), most recently in 2015 (2). In practice, revisions have been proposed and implemented by the European Environmental Contact Dermatitis Research Group (3) on behalf of the ESCD ([www.escd.org](http://www.escd.org)).

The contents of a generally recommended baseline series such as the EBS should be based on a sufficiently broad and valid evidence base. Another function of a baseline series should be to include extensions for adaptation to changes in environmental exposures at a local, regional or national level. Those extensions that prove useful for most investigators will provide incontrovertible evidence to support their inclusion into a core baseline series. The aim of this article is to stimulate debate on the current allergens included in the EBS, with the aim of creating a more open and responsive process for updating the series, using data provided by the European Surveillance System on Contact Allergies (ESSCA) to generate initial discussion.

## Method

The ESSCA network has already been described in previous publications (4). Briefly, clinical and demographic data, along with patch test results of the baseline series used in the departments, of all patients patch tested in the departments participating in the ESSCA are documented electronically in the local departments, by the use of diverse data capture software and partly the multilingual software WINALLDAT/ESSCA provided by the ESSCA (5). Anonymized data are pooled in the ESSCA data centre in Erlangen for further analysis (6) with R (version 3.3.2; [www.R-project.org](http://www.R-project.org)) software (7). Data from departmental and national extensions to the baseline series, together with some temporary additions, are also collated, provided that they have been tested in strictly consecutive patients to achieve comparability. These additional data may give an impression of the value of the respective allergens for future inclusion.

The study period was January 2013 to December 2014. The study included 12 European countries and, in total, 46 departments that contributed data on the EBS, with or without extensions and omissions. The present analysis is focused explicitly on allergens that were not part of the EBS that was valid at the time (8), but that have, however, been included in departmental and, preferably, national extensions to it, tested in consecutive patients. Hence, the present analysis is based on a subset

of participating departments (see Acknowledgements), as some departments contributed only EBS data.

Altogether, 31 689 patients were registered who had been tested with the EBS (with or without additions), with readings at least between day (D) 3 and D5. TRUE Test® employing a hydrocellulose matrix for the haptens instead of pet. or water had been used in a relatively small number of patients ( $n = 1214$ ), the vast majority of patients having been tested with pet.-based and water-based haptens, and investigator-loaded chamber systems. Moreover, two German departments use a 1-day patch test exposure, applied to 948 patients.

## Results

In the years 2013 and 2014, 31 689 patients were patch tested in the 46 European departments. The characteristics of this clinical population and patch test results obtained with the EBS have been published previously (9). As the Danish and Slovenian and a few other single department(s) shared data on results obtained with the EBS 'as is', they did not contribute to the present analysis. The frequencies of doubtful reactions, irritant reactions and different grades of positive reaction are shown in Table 1a–k for those allergens that were tested in more than one department.

Moreover, the following allergens were tested in consecutive patients in single departments, and yielded the following results; this includes allergens that had been tested in different concentrations in other departments and are shown in Table 1:

- Imidazolidinyl urea 1% pet. [Italy-11]: 1217 patients tested; one + reaction (0.1% positive).
- Bronopol (2-bromo-2-nitropropane-1,3-diol) 0.3% pet. (UK-99): 2503 patients tested; 2 ?+ reactions and 16 + reactions (0.6% positive).

Results obtained with allergens that were not part of the EBS obtained with TRUE Test® are shown in Table 2. Note that TRUE Test® had been used in < 20 patients in Basel (Switzerland) and Amsterdam VU (The Netherlands); these results have been omitted, as selective testing cannot be excluded. Therefore, the results are restricted to the three Spanish departments and Groningen, The Netherlands.

## Discussion

The results show that many departments and national groups already consider the current EBS to be a suboptimal screen, and use their own extensions to it. The haptens tested are, however, heterogeneous, although there are some consistent themes. In addition to being common,

**Table 1.** Pattern of reaction to allergens beyond the European baseline series valid during the study period tested in consecutive patients in more than one department of the European Surveillance System on Contact Allergies network. Allergens in *pet.*, except where indicated otherwise

| Department/country                        | n tested | % ?+/IR | % + | % ++/+++ | % positive | % stand. positive | 95%CI   |
|---|----------|---------|-----|----------|------------|-------------------|---------|
| (a) Sodium metabisulfite 1%               |          |         |     |          |            |                   |         |
| UK  | 5969     | 0.2     | 1.4 | 1.5      | 2.9        | 2.9               | 2.4–3.3 |
| NL-02                                     | 1969     | 1.3     | 4.6 | 0.4      | 5.0        | 4.9               | 3.9–5.8 |
| PL-01                                     | 200      | 0       | 0.5 | 1.0      | 1.5        | 1.6               | 0–3.5   |
| (b) Diazolidinyl urea 2%                  |          |         |     |          |            |                   |         |
| ES  | 1190     | 0       | 0.2 | 0.4      | 0.6        | 0.6               | 0.1–1.0 |
| NL  | 2568     | 0.4     | 0.9 | 0        | 0.9        | 0.9               | 0.5–1.3 |
| UK  | 6592     | 0.1     | 0.2 | 0.4      | 0.6        | 0.6               | 0.4–0.8 |
| DE-01                                     | 282      | 2.1     | 0.7 | 0        | 0.7        | 1.0               | 0–2.5   |
| IT-11                                     | 1217     | 0       | 0   | 0.1      | 0.1        | 0.1               | 0–0.2   |
| LT-01                                     | 256      | 0       | 0   | 0        | 0          | 0                 | 0–1.2   |
| PL-01                                     | 203      | 0       | 0   | 0.5      | 0.5        | 0.6               | 0–1.7   |
| (c) Imidazolidinyl urea 2%                |          |         |     |          |            |                   |         |
| ES  | 1190     | 0       | 0.2 | 0.4      | 0.6        | 0.6               | 0.1–1.0 |
| NL  | 2568     | 0.4     | 0.5 | 0.1      | 0.5        | 0.6               | 0.3–0.8 |
| UK  | 5903     | 0.1     | 0.1 | 0.1      | 0.2        | 0.2               | 0.1–0.3 |
| DE-01                                     | 283      | 0.7     | 0.4 | 0        | 0.4        | 0.7               | 0–2.2   |
| FI-01                                     | 231      | 0.4     | 0   | 0.4      | 0.4        | 0.3               | 0–0.8   |
| IT-02                                     | 576      | 0.2     | 0.7 | 0        | 0.7        | 0.6               | 0–1.3   |
| LT-01                                     | 256      | 0       | 0   | 0        | 0          | 0                 | 0–1.2   |
| PL-01                                     | 203      | 0       | 0   | 0.5      | 0.5        | 0.6               | 0–1.7   |
| (d) 2-Bromo-2-nitropropane-1,3-diol 0.25% |          |         |     |          |            |                   |         |
| UK  | 3401     | 0.1     | 0.8 | 0.2      | 0.9        | 0.9               | 0.6–1.3 |
| IT-11                                     | 1217     | 0       | 0.1 | 0        | 0.1        | 0.1               | 0–0.2   |
| LT-01                                     | 253      | 0       | 1.2 | 0.4      | 1.6        | 1.4               | 0–2.9   |
| (e) 2-Bromo-2-nitropropane-1,3-diol 0.5%  |          |         |     |          |            |                   |         |
| CH  | 1423     | 2.0     | 0.4 | 0.1      | 0.5        | 0.5               | 0.1–0.8 |
| DE  | 1924     | 1.0     | 0.5 | 0.1      | 0.6        | 0.6               | 0.2–0.9 |
| AT-25                                     | 292      | 0.3     | 0   | 0.3      | 0.3        | 0.3               | 0–0.8   |
| ES-01                                     | 766      | 0       | 0.4 | 0.7      | 1.0        | 1.2               | 0.3–2.1 |
| LT-01                                     | 3        | 0       | 0   | 0        | 0          | 0                 | 0–63.2  |
| NL-01                                     | 599      | 0       | 0   | 0        | 0          | 0                 | 0–0.5   |
| UK-08                                     | 1293     | 0.3     | 0.5 | 0.2      | 0.7        | 0.7               | 0.2–1.2 |
| (f) Propolis 10%                          |          |         |     |          |            |                   |         |
| CH  | 2675     | 10.8    | 3.1 | 1.2      | 4.4        | 4.1               | 3.3–4.9 |
| DE  | 3547     | 8.1     | 2.9 | 0.9      | 3.7        | 3.4               | 2.7–4.0 |
| PL  | 1816     | 0.8     | 2.0 | 0.8      | 2.8        | 2.9               | 2.1–3.6 |
| UK  | 2090     | 0.1     | 0.2 | 0        | 0.3        | 0.3               | 0.1–0.5 |
| AT-25                                     | 509      | 1.6     | 5.9 | 0.4      | 6.3        | 5.6               | 3.6–7.7 |
| IT-02                                     | 576      | 0.3     | 0.9 | 1.2      | 2.1        | 2.1               | 0.9–3.3 |
| LT-01                                     | 256      | 0       | 0.4 | 0.4      | 0.8        | 0.7               | 0–1.9   |
| (g) Oil of turpentine 10%                 |          |         |     |          |            |                   |         |
| CH  | 2672     | 1.4     | 0.7 | 0.4      | 1.1        | 1.0               | 0.6–1.3 |
| DE  | 3555     | 1.8     | 1.1 | 0.3      | 1.3        | 1.1               | 0.8–1.5 |
| AT-25                                     | 509      | 0.4     | 2.0 | 0.2      | 2.2        | 1.7               | 0.7–2.7 |
| (h) Compositae mix 2.5%                   |          |         |     |          |            |                   |         |
| UK  | 3464     | 0       | 0.6 | 0.5      | 1.1        | 1                 | 0.7–1.4 |
| FI-01                                     | 232      | 0       | 0   | 0        | 0          | 0                 | 0–1.3   |
| (i) Compositae mix 5%                     |          |         |     |          |            |                   |         |
| CH  | 2698     | 1.1     | 0.7 | 0.5      | 1.2        | 1                 | 0.7–1.4 |
| DE  | 3590     | 1.5     | 1.0 | 1.1      | 2.1        | 2.0               | 1.5–2.5 |
| AT-25                                     | 510      | 0.4     | 2.9 | 0.2      | 3.1        | 2.9               | 1.3–4.4 |
| IT-01                                     | 4        | 0       | 0   | 0        | 0          | 0                 | 0–52.7  |

**Table 1.** Continued

| Department/country    | n tested | % ?+/IR | % + | % ++/+++ | % positive | % stand. positive | 95%CI   |
|-----------------------|----------|---------|-----|----------|------------|-------------------|---------|
| (j) Compositae mix 6% |          |         |     |          |            |                   |         |
| IT                    | 951      | 0.4     | 0.2 | 0.1      | 0.3        | 0.2               | 0–0.5   |
| (k) Caine mix III 10% |          |         |     |          |            |                   |         |
| UK                    | 7197     | 0.3     | 0.4 | 0.4      | 0.9        | 0.8               | 0.6–1.1 |
| FI-01                 | 231      | 2.2     | 0.4 | 0.4      | 0.9        | 1                 | 0–2.4   |
| PL-02                 | 1613     | 0.5     | 2.1 | 0.4      | 2.5        | 2.7               | 1.9–3.6 |
| (l) Carba mix 3%      |          |         |     |          |            |                   |         |
| ES                    | 1723     | 0.1     | 0.8 | 1.1      | 2.0        | 2.0               | 1.3–2.7 |
| IT                    | 1737     | 2.1     | 3.6 | 0.5      | 4.0        | 4.2               | 3.3–5.2 |
| NL-02                 | 1969     | 4.8     | 7.8 | 0.5      | 8.2        | 8.2               | 7.0–9.5 |
| UK                    | 7197     | 0.3     | 1.0 | 0        | 1.0        | 1.0               | 0.8–1.2 |

AT, Austria; CH, Switzerland; CI, confidence interval; DE, Germany; ES, Spain; FI, Finland; IR, irritant reaction; IT, Italy; LT, Lithuania; NL, The Netherlands; PL, Poland; UK, United Kingdom; Stand., standardized for age and sex.

**Table 2.** Patch test results obtained with the allergens from TRUE Test<sup>®</sup> that are not part of the European baseline series valid during the study period. The maximum reading between day (D) 3 and D5 (inclusive) was considered

| Department/country             | n tested | % ?+/IR | % + | % ++/+++ | % positive | % stand. positive | 95%CI    |
|--------------------------------|----------|---------|-----|----------|------------|-------------------|----------|
| (a) Diazolidinyl urea          |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 0.7 | 0        | 0.7        | 1.0               | 0–2.0    |
| NL-01                          | 599      | 0.3     | 0.3 | 0        | 0.3        | 0.3               | 0–0.8    |
| (b) Imidazolidinyl urea        |          |         |     |          |            |                   |          |
| ES                             | 570      | 0.2     | 0.4 | 0        | 0.4        | 0.5               | 0–1.2    |
| NL-01                          | 599      | 0.8     | 0.2 | 0        | 0.2        | 0.2               | 0–0.5    |
| (c) Quinoline mix              |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 0.4 | 0        | 0.4        | 0.3               | 0–0.6    |
| (d) Ethylenediamine HCl        |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 0.2 | 0.7      | 0.9        | 1.0               | 0–1.9    |
| NL-01                          | 599      | 1.3     | 0.5 | 0.2      | 0.7        | 0.6               | 0–1.2    |
| (e) Thiomersal                 |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 1.8 | 4.7      | 6.5        | 7.8               | 5.2–10.4 |
| NL-01                          | 599      | 0.5     | 0.3 | 0.3      | 0.7        | 0.6               | 0–1.3    |
| (f) Caine mix                  |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 0.2 | 2.3      | 2.5        | 2.2               | 1.0–3.4  |
| NL-01                          | 599      | 0.5     | 0.8 | 0.2      | 1.0        | 0.9               | 0.2–1.6  |
| (g) Hydrocortisone 17-butyrate |          |         |     |          |            |                   |          |
| ES                             | 570      | 0       | 0.2 | 0        | 0.2        | 0.1               | 0–0.4    |
| NL-01                          | 599      | 2.3     | 0.3 | 0        | 0.3        | 0.3               | 0–0.7    |
| (h) Carba mix                  |          |         |     |          |            |                   |          |
| ES                             | 570      | 0.4     | 1.4 | 0.5      | 1.9        | 2.6               | 1.0–4.2  |
| NL-01                          | 599      | 2.2     | 2.7 | 1.0      | 3.7        | 3.3               | 1.9–4.6  |

CI, confidence interval; ES, Spain; IR, irritant reaction; NL, The Netherlands; Stand., standardized for age and sex.

screening haptens need to be relevant, and an assessment of this in one centre is shown in Table 3. The article of Bruze et al. (1) recommends inclusion when the contact allergy prevalence is 0.5–1% and above.

#### Allergens to add

*Sodium metabisulfite 1% pet.* was tested in the baseline series of three countries, with a percentage of positive

reactions (Table 1) potentially justifying inclusion in the baseline series. There appears to be agreement that a 1% concentration is the most sensitive (10) and is a marker of allergy to other sulfites (11, 12). Although relevance can be hard to establish (13), the frequency of reactions is such that inclusion in the baseline series should be considered, with this preservative being widely used in cosmetic products, medicaments, industry, and food.

**Table 3.** Proposed changes to the baseline series with results of testing with the baseline series of one UK centre during 2016 in 1019 patients. Additional haptens in bold have a prevalence that is insufficient to warrant further inclusion. All allergens in pet.

|   | % Positive          | 95%CI     | % CR | % PR/NR |
|---|---------------------|-----------|------|---------|
| Hapten to add (based on our data)               |                     |           |      |         |
| Sodium metabisulfite 1%                         | 2.9                 | 1.9–4.1   | 1.8  | 1.1     |
| 2-Bromo-2-nitropropane-1,3-diol (Bronopol) 0.5% | 0.39                | 0.11–1.0  | 0.29 | 0.10    |
| Diazolidinyl urea 2%                            | 0.79                | 0.34–1.5  | 0.69 | 0.10    |
| Imidazolidinyl urea 2%                          | 0.39                | 0.11–1.0  | 0.39 | 0       |
| Propolis 10%                                    | 1.3                 | 0.68–2.2  | 1.2  | 0.10    |
| Compositae mix 5% or 6%                         | 0.49 <sup>a,b</sup> | 0.16–1.1  | 0.29 | 0.20    |
| Carba mix 3%                                    | 0.98                | 0.47–1.8  | 0.69 | 0.30    |
| <b>1,3-Diphenylguanidine 1%</b>                 | 0.1                 | 0–0.55    | 0.10 | 0       |
| Hapten to add (based on the literature)         |                     |           |      |         |
| 2-Hydroxyethyl methacrylate 2%                  | 1.4                 | 0.75–2.3  | 0.98 | 0.39    |
| Linalool hydroperoxide 1%                       | 4.7                 | 3.49–6.2  | 4.2  | 0.49    |
| Limonene hydroperoxide 0.3%                     | 4.3                 | 3.15–5.8  | 3.9  | 0.39    |
| <b>Melaleuca alternifolia 5%</b>                | 0.29                | 0.06–0.86 | 0.29 | 0       |
| <b>Mentha piperita 2%</b>                       | 0.22                | 0.02–0.71 | 0.20 | 0       |
| <i>Santalum album</i> 2%                        | 0.59                | 0.22–1.3  | 0.49 | 0.1     |
| Hapten to switch                                |                     |           |      |         |
| Caine mix III 10%                               | 0.39                | 0.11–1.0  | 0.2  | 0.1     |
| Black rubber mix 0.6%                           | NT                  | –         | –    | –       |
| Hapten to delete                                |                     |           |      |         |
| Clioquinol 5%                                   | 0.1 <sup>c</sup>    | 0–0.55    | 0.1  | 0       |
| Primin 0.01%                                    | NT                  | –         | –    | –       |

<sup>a</sup>Compositae mix tested at 2.5%.

<sup>b</sup>Sesquiterpene lactone mix 0.1% pet. gave 0.29% positive reactions by comparison.

<sup>c</sup>Quinoline mix 6% pet. tested.

CI, confidence interval; CR, current relevance; NR, not relevant; NT, not tested; PR, past relevance.

*Formaldehyde releasers*: diazolidinyl urea, imidazolidinyl urea and Bronopol (2-bromo-2-nitropropane-1,3-diol) are already added to an extended baseline series in many countries (Table 1). The frequency of positive reactions would appear to justify inclusion. These formaldehyde-releasing preservatives are commonly not suspected clinically, and have been included in national baseline series in several countries (14, 15).

*Fragrance(s)* are currently screened within the baseline series, but there is a recognition that the current screen is inadequate. Individual groups have taken varying approaches, including testing of multiple individual fragrance allergens, namely, those 26 fragrances that currently need to be labelled according to the Cosmetics Regulation (16), testing with oxidized allergens, especially those of limonene and linalool (17), and using essential oils (18). It seems likely that testing with limonene hydroperoxide 0.3% pet. and linalool hydroperoxide 1% pet. (19) together with oils of *Melaleuca alternifolia*, *Mentha piperita* and *Santalum album* (20) (which contain allergens predominantly other than those in the baseline series plus limonene and linalool) might be a way of maximizing yield while minimizing the number of additional allergens tested. However, the

irritancy of hydroperoxides is an issue at the concentrations mentioned. A recent study testing routinely with all 26 allergens that require labelling showed that, in addition to linalool and limonene hydroperoxides, *Evernia furfuracea* yielded a significant number of additional relevant reactions (21). The routine testing of the 26 substances that currently need to be labelled – with limonene and linalool in their oxidized forms – or at least of those of these haptens that have proven to be important in terms of frequency of sensitization can be viewed as a useful strategy. From a practical perspective, both previous exposure and, thus, relevance can be verified, and future avoidance can be managed, thanks to the labelling. Although we may not yet have identified an ideal combination, given the high frequency of false-negative results for fragrance allergy when only the current screening fragrance mixes are used, it seems essential to add additional fragrance allergens to an extended baseline series.

*Propolis 10% pet.* was tested in seven countries (Table 1), with, apart from the United Kingdom, a frequency of reactions justifying inclusion. Notwithstanding the current low prevalence of positives in the United Kingdom, in the past propolis has been included



in the British baseline series (22), when the prevalence of allergy was 1.9% among those tested. Patients who are allergic to propolis frequently co-react with colophonium and fragrances (23), and, given the current popularity of 'natural' products and its widespread use (24), it would seem that more extensive testing throughout Europe may be justified.

*Compositae mix 5/6% pet.* has been recognized as being a useful supplement to sesquiterpene lactone mix 0.1% pet. for detection of allergy to members of the Compositae/Asteraceae family of plants (25, 26). Although some have found that the additional yield over and above sesquiterpene lactone mix alone is insufficient to warrant additional testing in a baseline series in Sweden (27), the notion remains that sesquiterpene lactone mix alone is an inadequate screen (28, 29), warranting further study. The commercial allergen tested at 5% has also been shown to be sensitizing (30), with equal numbers of patients being sensitized and additional allergic patients detected. This is not a property desirable for any screening allergen. In the United Kingdom, a lower concentration of Compositae mix II, that is, 2.5% pet. (Chemotechnique Diagnostics, Vellinge, Sweden), has been included in the baseline series for many years, without evidence of active sensitization, but continued sensitivity in the detection of Compositae allergy (Table 3).

*1,3-Diphenylguanidine 1% pet.* is a rubber accelerator contained within the 'carba mix', although it is not a dithiocarbamate. Recent studies of rubber allergy from the ESSCA (31) and EPIDERM (32) suggest that carba mix is causing more frequent allergic reactions, although concerns have been raised about the irritancy of the patch test preparation. Many manufacturers of gloves have switched from thiuram to carbamates as accelerators, raising the possibility that carbamates, as a consequence of increased exposure, may be sensitizing more frequently. However, thiuram mix is thought to be an adequate screen for carbamate allergy (33), as both exist as a redox pair in equilibrium *in vivo*, with thiuram mix being the better marker of contact allergy (34). Consequently, it is thought that 1,3-diphenylguanidine may be responsible for the increasing prevalence of reactions to the carba mix. Although there is no definitive answer, consideration should be given to testing more widely with zinc diethyldithiocarbamate 1% pet. and 1,3-diphenylguanidine to avoid false-negative reactions. However, given the low yield from testing with 1,3-diphenylguanidine alone (Table 3), it may be better to restrict this to a rubber series (35) and patients with hand dermatitis.

*2-Hydroxyethyl methacrylate (2-HEMA) 2% pet.* has previously been used as a marker of contact

allergy to methacrylates (36). Traditionally, exposure was occupational, but the recent fashion for acrylate-containing nail products is resulting in increases in the numbers of cases of non-occupational hand and facial dermatitis (37, 38). Although data on systematic testing in the current environment do not exist, it seems probable that consideration needs to be given to evaluating more extensive testing with acrylates to avoid missing what is becoming an increasingly common contact allergen in a domestic setting. In the previous study from 2008 (14), 63% of sensitized patients would have been missed if acrylates had not been tested routinely. Sensitization is also a concern when acrylates are tested (39). The high frequency of sensitization reported was attributable to various acrylates, that is, ethyl acrylate, 2-hydroxy ethyl acrylate, etc., and not to methacrylates such as 2-HEMA. After testing of > 1000 patients with 2-HEMA in a baseline series, no cases of active sensitization became apparent (Table 3), even though patients are encouraged to return if they develop late reactions. As users of acrylate nails are predominantly female, another way to reduce exposure and sensitization risk would be to create a sex-specific baseline series.

#### Allergens to switch

*Caine mix III 10% pet.* This mix, containing benzocaine, cinchocaine (dibucaine), and tetracaine, the latter two as hydrochlorides, has long been used instead of benzocaine 5% pet. in the baseline series in the United Kingdom (40, 41). Data from the ESSCA, as they do not provide a direct comparison, are unable to confirm that more widespread use of caine mix III across Europe would be beneficial, but do suggest that instituting a more widespread comparison would be of value. In general, those centres of the ESSCA testing caine mix III had a higher yield of positive results than obtained with benzocaine 5% pet. (8) during the same time period. Lidocaine (lignocaine) is an amide local anaesthetic that does not cross-react. However, there are increasing reports of contact allergy; in one study, when lidocaine was included in a medicament series, there were more cases of contact allergy to lidocaine than to other topical anaesthetic agents (42). This suggests that the usefulness of including lidocaine as a screening agent should be evaluated.

*Black rubber mix 0.6% pet.* may prove a better screen for rubber antioxidants than *N*-isopropyl-*N'*-phenyl-*p*-phenylenediamine (IPPD) 0.1% pet. (31) alone. A prospective comparison may help to provide evidence of the superiority of one above the other, ideally based on thorough relevance assessment and/or breakdown testing of mix constituents.

## Allergens to omit

Testing with the baseline series in departments of the ESSCA during 2013–2014 suggests that two allergens in particular should be considered for removal from the EBS.

*Primin 0.01% pet.*, with an age- and sex-standardized prevalence of allergy of 0.2% (95%CI: 0.2–0.3%), no longer appears to warrant inclusion. The development of hypoallergenic varieties of *Primula obconica* and the subsequent reduction in the frequency of contact allergy to the plant is well documented (43). However, patch testing may still be relevant in subgroups of the population (e.g. retirees and household workers in Italy) (44), and addition to a plant series may be a better option for more selected testing.

*Clioquinol 5% pet.*, with an age- and sex-standardized prevalence of allergy of 0.3% (95%CI: 0.2–0.4%), also appears to yield insufficient allergic reactions to warrant continued inclusion. This probably reflects changing pre-

scribing habits and an aversion to the yellow staining of this topical antiseptic, exposure to which may quite easily be identified by proper history-taking, enabling aimed testing as indicated.

## Conclusion

It is hoped that the above discussion has highlighted some areas for further investigation. We propose that a (temporary) (45) supplement to the baseline series (Table 3) might prove to be a useful way of evaluating the need to test more widely, and prove to be a practical way of being more responsive to changes in environmental allergen exposure while further information is gathered.

It is inevitable that there will be regional and national differences requiring additions to the above, depending on local exposures, that national societies will continue to recommend: for instance, ethylenediamine dihydrochloride remaining in the Spanish baseline series (46).

## References

- Bruze M, Condé-Salazar L, Goossens A et al. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. *Contact Dermatitis* 1999; **41**: 241–250.
- Isaksson M, Ryberg K, Goossens A, Bruze M. Recommendation to include a textile dye mix in the European baseline series. *Contact Dermatitis* 2015; **73**: 15–20.
- Bruynzeel D P, Diepgen T L, Andersen K E et al. Monitoring the European standard series in 10 centres 1996–2000. *Contact Dermatitis* 2005; **53**: 146–149.
- Uter W, Rämisch C, Aberer W et al. The European baseline series in 10 European Countries, 2005/2006: results of the European Surveillance System on Contact Allergies (ESSCA). *Contact Dermatitis* 2009; **61**: 31–38.
- Uter W, Arnold R, Wilkinson J et al. A multilingual European patch test software concept: WinAllDat/ESSCA. *Contact Dermatitis* 2003; **49**: 270–271.
- Uter W, Schnuch A, Wilkinson M et al. Registries in clinical epidemiology: the European Surveillance System on Contact Allergies (ESSCA). *Methods Inf Med* 2016; **55**: 193–199.
- R-Team. *R: A Language and Environment for Statistical Computing*. Vienna, R Foundation for Statistical Computing, 2016.
- Bruze M, Goossens A, Isaksson M. Recommendation to increase the test concentration of methylchloroisothiazolinone/methylisothiazolinone in the European baseline patch test series – on behalf of the European Society of Contact Dermatitis and the European Environmental and Contact Dermatitis Research Group. *Contact Dermatitis* 2014; **71**: 35–40.
- Uter W, Balato A, Ballmer-Weber B et al. ESSCA (European Surveillance System on Contact Allergies) results with the European baseline series, 2013/14. *J Eur Acad Dermatol Venereol* 2017; **31**: 1516–1525.
- Ralph N, Verma S, Merry S et al. What is the relevance of contact allergy to sodium metabisulfite and which concentration of the allergen should we use? *Dermatitis* 2015; **26**: 162–165.
- Oliphant T, Mitra A, Wilkinson M. Contact allergy to sodium sulfite and its relationship to sodium metabisulfite. *Contact Dermatitis* 2012; **66**: 128–130.
- Roberts D W, Basketter D, Kimber I et al. Sodium metabisulfite as a contact allergen: an example of a rare chemical mechanism for protein modification. *Contact Dermatitis* 2012; **66**: 123–127.
- García-Gavín J, Parente J, Goossens A. Allergic contact dermatitis caused by sodium metabisulfite: a challenging allergen: a case series and literature review. *Contact Dermatitis* 2012; **67**: 260–269.
- Toholka R, Wang Y S, Tate B et al. The first Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis. *Australas J Dermatol* 2015; **56**: 107–115.
- Warshaw E M, Maibach H I, Taylor J S et al. North American Contact Dermatitis Group patch test results: 2011–2012. *Dermatitis* 2015; **26**: 49–59.
- Mann J, McFadden J P, White J M et al. Baseline series fragrance markers fail to predict contact allergy. *Contact Dermatitis* 2014; **70**: 276–281.
- Audrain H, Kenward C, Lovell C R et al. Allergy to oxidized limonene and linalool is frequent in the UK. *Br J Dermatol* 2014; **171**: 292–297.
- Warshaw E M, Zug K A, Belsito D V et al. Positive patch-test reactions to essential oils in consecutive patients: results from North America and Central Europe. *Dermatitis* 2017; **28**: 246–252.
- Bråred Christensson J, Karlberg A T, Andersen K E et al. Oxidized limonene and oxidized linalool: concomitant contact allergy to common fragrance terpenes. *Contact Dermatitis* 2016; **74**: 273–280.
- Sabroe R A, Holden C R, Gawkrödger D J. Contact allergy to essential oils cannot always be predicted from allergy to fragrance markers in the baseline series. *Contact Dermatitis* 2016; **74**: 236–241.
- Bennike N H, Zachariae C, Johansen J D. Non-mix fragrances are top sensitizers in consecutive dermatitis patients – a cross-sectional study of the 26 EU-labelled fragrance allergens. *Contact Dermatitis* 2017; **77**: 270–279.



- 22 Rajpara S, Wilkinson M S, King C M et al. The importance of propolis in patch testing – a multicentre survey. *Contact Dermatitis* 2009; **61**: 287–290.
- 23 Shi Y, Nedorost S, Scheman L, Scheman A. Propolis, colophony, and fragrance cross-reactivity and allergic contact dermatitis. *Dermatitis* 2016; **27**: 123–126.
- 24 de Groot A C. Propolis: a review of properties, applications, chemical composition, contact allergy, and other adverse effects. *Dermatitis* 2013; **24**: 263–282.
- 25 Paulsen E, Andersen K E, Hausen B M. An 8-year experience with routine SL mix patch testing supplemented with Compositae mix in Denmark. *Contact Dermatitis* 2001; **45**: 29–35.
- 26 Bong J L, English J S, Wilkinson S M. Diluted Compositae mix versus sesquiterpene lactone mix as a screening agent for Compositae dermatitis: a multicentre study. *Contact Dermatitis* 2001; **45**: 26–28.
- 27 Isaksson M, Hansson C, Inerot A et al. Multicentre patch testing with compositae mix by the Swedish Contact Dermatitis Research Group. *Acta Derm Venereol* 2011; **91**: 295–298.
- 28 Paulsen E, Andersen K E. Screening for Compositae sensitization with pure allergens: implications of molecular structure, strength of reaction, and time of testing. *Contact Dermatitis* 2011; **64**: 96–103.
- 29 Jacob M, Brinkmann J, Schmidt T J. Sesquiterpene lactone mix as a diagnostic tool for Asteraceae allergic contact dermatitis: chemical explanation for its poor performance and Sesquiterpene lactone mix II as a proposed improvement. *Contact Dermatitis* 2012; **66**: 233–240.
- 30 Wilkinson S M, Pollock B. Patch test sensitisation after use of the Compositae mix. *Contact Dermatitis* 1999; **40**: 277–278.
- 31 Uter W, Warburton K, Weisshaar E et al. Patch test results with rubber series in the European Surveillance System on Contact Allergies (ESSCA), 2013/14. *Contact Dermatitis* 2016; **75**: 345–352.
- 32 Warburton K L, Urwin R, Carder M et al. UK rates of occupational skin disease attributed to rubber accelerators, 1996–2012. *Contact Dermatitis* 2015; **72**: 305–311.
- 33 Aalto-Korte K, Pesonen M. Patterns of simultaneous patch test reactions to thiurams and dithiocarbamates in 164 patients. *Contact Dermatitis* 2016; **75**: 353–357.
- 34 Hansson C, Pontén A, Svedman C, Bergendorff O. Reaction profile in patch testing with allergens formed during vulcanization of rubber. *Contact Dermatitis* 2014; **70**: 300–308.
- 35 Warburton K L, Uter W, Geier J et al. Patch testing with rubber series in Europe: a critical review and recommendation. *Contact Dermatitis* 2017; **76**: 195–203.
- 36 Goon A T, Bruze M, Zimerson E et al. Screening for acrylate/methacrylate allergy in the baseline series: our experience in Sweden and Singapore. *Contact Dermatitis* 2008; **59**: 307–313.
- 37 Montgomery R, Stocks S J, Wilkinson S M. Contact allergy resulting from the use of acrylate nails is increasing in both users and those who are occupationally exposed. *Contact Dermatitis* 2016; **74**: 120–122.
- 38 Dahlin J, Berne B, Dunér K et al. Several cases of undesirable effects caused by methacrylate ultraviolet-curing nail polish for non-professional use. *Contact Dermatitis* 2016; **75**: 151–156.
- 39 Kanerva L, Estlander T, Jolanki R. Sensitization to patch test acrylates. *Contact Dermatitis* 1988; **18**: 10–15.
- 40 Beck M H, Holden A. Benzocaine – an unsatisfactory indicator of topical local anaesthetic sensitization for the UK. *Br J Dermatol* 1988; **118**: 91–94.
- 41 Sidhu S K, Shaw S, Wilkinson J D. A 10-year retrospective study on benzocaine allergy in the United Kingdom. *Am J Contact Dermat* 1999; **10**: 57–61.
- 42 Spring S, Pratt M, Chaplin A. Contact dermatitis to topical medicaments: a retrospective chart review from the Ottawa Hospital Patch Test Clinic. *Dermatitis* 2012; **23**: 210–213.
- 43 Zachariae C, Engkilde K, Johansen J D, Menné T. Primin in the European standard patch test series for 20 years. *Contact Dermatitis* 2007; **56**: 344–346.
- 44 Bongiorni L, Prodi A, Rui F et al. Primin sensitization in north-eastern Italy: a temporal trend from 1996 to 2012. *Contact Dermatitis* 2015; **73**: 108–112.
- 45 Aberer W, Komericki P, Uter W et al. Epidemiologic surveillance of contact allergens. The 'monitoring series' of IVDK (Information Network of Dermatologic Clinics). *Hautarzt* 2003; **54**: 741–749.
- 46 Hervella-Garcés M, García-Gavín J, Silvestre-Salvador J F. The Spanish standard patch test series: 2016 update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). *Actas Dermosifiliogr* 2016; **107**: 559–566.